+249.5%
MRVL vs MRNA
+511.3%
-261.8%
-48.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.0% | -2.2% | +9.3% | +7.2% |
| 7D | +3.2% | +5.5% | -2.3% | +2.8% |
| 30D | +5.9% | +158.7% | -152.8% | -7.0% |
| 3M | -29.3% | +182.1% | -211.5% | -39.4% |
| 6M | +186.5% | +151.8% | +34.7% | +147.1% |
| YTD | +163.4% | +393.6% | -230.1% | +118.5% |
| 1Y | +249.5% | +499.5% | -250.0% | +192.0% |
| All | +249.5% | +511.3% | -261.8% | +192.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling